Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MaxCyte, Inc. - Common Stock (NQ: MXCT )

4.170 +0.100 (+2.46%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MaxCyte, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
7 Must-Buy Penny Stocks to Add to Your Portfolio in 2023
For those that want to take a journey on the wild side of the market, these penny stocks may offer significant upside rewards. 
Via InvestorPlace
MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Earnings Perspective: Return On Capital Employed
Via Benzinga
MaxCyte Expects Q1 Sales To Beat Expectations, CFO Resigns
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap... 
Via Benzinga
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
MaxCyte’s Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran’s TAILWIND® platform for novel CAR-NK cell therapies 
From MaxCyte, Inc
Via GlobeNewswire
7 Hot Stocks to Book Profits In Before 2023
With major macroeconomic headwinds appearing on the horizon, it’s time for investors to consider the hot stocks to book profits in. 
Via InvestorPlace
MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases
Curamys to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to help advance its cell fusion technology. 
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Reports Third Quarter 2022 Financial Results
From MaxCyte, Inc
Via GlobeNewswire
Earnings Outlook For MaxCyte
MaxCyte (NASDAQ:MXCT) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that MaxCyte will... 
Via Benzinga
MaxCyte to Participate in Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders
MaxCyte Inc (NASDAQ: MXCT) has signed a  
Via Benzinga
MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program
From MaxCyte, Inc
Via GlobeNewswire
Recap: MaxCyte Q2 Earnings
  MaxCyte (NASDAQ:MXCT) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings MaxCyte reported in-line EPS of... 
Via Benzinga
A Preview Of MaxCyte's Earnings
  MaxCyte (NASDAQ:MXCT) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement. Analysts estimate that MaxCyte will... 
Via Benzinga
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
Earnings Scheduled For May 9, 2022
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million. 
Via Benzinga
MaxCyte's Return On Capital Employed Insights
Benzinga Pro data, MaxCyte (NASDAQ:MXCT) reported Q4 sales of $10.15 million. Earnings fell to a loss of $4.87 million, resulting in a 81.85% decrease from last quarter. MaxCyte... 
Via Benzinga
Earnings Scheduled For March 22, 2022
Companies Reporting Before The Bell • GDS Holdings (NASDAQ:GDS) is projected to report quarterly loss at $0.18 per share on revenue of $338.69 million. • HUYA (... 
Via Benzinga
11 Health Care Stocks Moving In Monday's Intraday Session
Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) shares rose 35.6% to $2.17 during Monday's regular session. The current volume of 5.6 million shares is 531.8% of Aridis... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Pasithea Therapeutics (NASDAQ:KTTA 
Via Benzinga
MaxCyte, Inc. (MXCT) Q3 2021 Earnings Call Transcript
MXCT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
91 Biggest Movers From Yesterday
Gainers NuZee, Inc. (NASDAQ: NUZE) shares jumped 164.5% to settle at $5.29 on Thursday. NuZee manufacturing partner, Cuvee Coffee, reported an expansion into select Walmart... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Liquidia (NASDAQ:LQDA) stock inc... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 55.11% to $1.11 during Monday's pre-market session. The company's market cap stands at $27.1... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, investor! We're starting off the trading week with a breakdown of the biggest pre-market stock movers for Monday! 
Via InvestorPlace
28 Stocks Moving In Friday's Mid-Day Session
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers ChemoCentryx (NASDAQ:CCXI) shares rose 77.65% to $34.82 during Friday's pre-market session. The company's market cap stands at $2.4 billion. eFFECTOR... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.